Understanding Your Pathology Report
At a Glance
A basal cell carcinoma biopsy examines only part of a skin lesion, so a clear biopsy margin does not prove the cancer is gone and the most aggressive growth pattern may not be sampled. Review the subtype, margins, nerve involvement, and whether the biopsy was transected with your doctor.
A pathology report is an essential guide to your diagnosis. It is created by a pathologist or dermatopathologist—a doctor who studies your tissue under a microscope to identify exactly what the cells are doing [1]. While your biopsy confirmed you have Basal Cell Carcinoma (BCC), it is important to understand that an initial diagnostic biopsy is often just a “snapshot” or a sample of a larger picture [2].
How Your Biopsy Was Performed
There are two primary ways a doctor takes a sample of a suspected BCC:
- Shave Biopsy: The doctor uses a small blade to “shave” off the top layers of the skin. This is common for raised or bumpy lesions [3].
- Punch Biopsy: The doctor uses a tool similar to a tiny cookie cutter to remove a deep cylinder of skin. This is often used if the doctor needs to see deeper into the tissue [3].
The Challenge of “Sampling Error”
Because an initial biopsy is a partial sample, it may not show the whole story. BCC often grows in a mixed pattern, meaning one part of the tumor might be a “quiet” nodular type, while another unsampled part is a more “aggressive” infiltrative type [2][4].
Various studies highlight that initial biopsies can sometimes underestimate the aggressiveness of a tumor. For instance, in specific study populations, an aggressive component was missed in a significant portion of initial biopsies, and up to 30% of tumors initially called “low-risk” were later reclassified as “high-risk” once the entire lesion was surgically removed and examined [2][5]. These are study-specific estimates, not a guarantee that your tumor has hidden cancer, but they explain why your surgeon may recommend a comprehensive removal technique even if the biopsy looks low-risk.
Key Terms on Your Report
Your report will contain technical terms that describe the behavior of the cancer:
- Subtype: This describes the growth pattern (e.g., Nodular, Superficial, Infiltrative). If multiple types are present, the report should ideally list the most aggressive one [6].
- Margins: This tells you if the cancer cells reach the edge of the tissue sample. Note: Interpreting margins on a partial biopsy is different from a final surgical excision.
- Clear/Negative: No tumor was seen at the edge of the sample. On a biopsy, this does not prove the entire BCC is gone from your body; it just means the sample’s edge is clear [7].
- Involved/Positive: The cancer reaches the edge; residual tumor may remain in your skin [7].
- Close: The cancer is near the edge.
- Perineural Invasion (PNI): This means cancer cells are growing around or along a nerve. This is a high-risk feature [8][9].
- Transected: This means the biopsy cut right through the tumor. If a biopsy is “transected at the base,” the pathologist cannot tell you the true depth of invasion (how deep the cancer goes) because the bottom of the tumor was left behind in the skin [10].
Your Pathology Checklist
When reviewing your report with your doctor, ensure these data points are included for a complete assessment [1][6]:
- Diagnostic Site: Exactly where on your body the sample was taken.
- Histologic Subtype: The specific growth pattern(s) identified.
- Aggressive Features: Clear mention of whether infiltrative, micronodular, or morpheaform patterns are present.
- Margin Status: Whether the edges of the sample are clear, close, or involved.
- Perineural/Lymphovascular Invasion: A statement on whether nerve or vessel involvement was seen.
Understanding these details helps you and your care team determine your definitive treatment plan [11].
Common questions in this guide
Can a biopsy miss the most aggressive part of basal cell carcinoma?
What does a clear margin mean on a BCC biopsy?
What does “transected at the base” mean in a pathology report?
How are shave and punch biopsies different for BCC?
Which details should I look for in my BCC pathology report?
What is perineural invasion in basal cell carcinoma?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on skin basal cell carcinoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Given that my biopsy was a sample, how confident are you that we have identified the most aggressive subtype present in the tumor?
- 2.My report mentions a specific subtype, but could there be a hidden infiltrative component that this partial biopsy didn't capture?
- 3.What is the exact margin status on the biopsy, and how does that influence our definitive treatment plan?
- 4.Was there any evidence of perineural invasion or lymphovascular invasion found in the tissue sample?
- 5.Since my biopsy was 'transected' at the base, does that mean we don't know how deep the cancer actually goes?
References
References (11)
- 1
Guidelines of care for the management of basal cell carcinoma.
, , Kim JYS, et al.
Journal of the American Academy of Dermatology 2018; (78(3)):540-559 doi:10.1016/j.jaad.2017.10.006.
PMID: 29331385 - 2
Accuracy of Biopsy in Subtyping Periocular Basal Cell Carcinoma.
Sun MT, Wu A, Huilgol SC, Selva D
Ophthalmic plastic and reconstructive surgery 2015; (31(6)):449-51 doi:10.1097/IOP.0000000000000372.
PMID: 25794023 - 3
Basal Cell and Cutaneous Squamous Cell Carcinomas: Diagnosis and Treatment.
Firnhaber JM
American family physician 2020; (102(6)):339-346.
PMID: 32931212 - 4
Biopsy outperforms reflectance confocal microscopy in diagnosing and subtyping basal cell carcinoma: results and experiences from a randomized controlled multicentre trial.
Woliner-van der Weg W, Peppelman M, Elshot YS, et al.
The British journal of dermatology 2021; (184(4)):663-671 doi:10.1111/bjd.19381.
PMID: 32628771 - 5
Detection of High-Risk Histologic Features and Tumor Upstaging of Nonmelanoma Skin Cancers on Debulk Analysis: A Quantitative Systematic Review.
Singh B, Dorelles A, Konnikov N, Nguyen BM
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 2017; (43(8)):1003-1011 doi:10.1097/DSS.0000000000001146.
PMID: 28654579 - 6
Position paper on a simplified histopathological classification of basal cell carcinoma: results of the European Consensus Project.
Fernández-Figueras MT, Malvehi J, Tschandl P, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV 2022; (36(3)):351-359 doi:10.1111/jdv.17849.
PMID: 34931722 - 7
Margins in head and neck non-melanoma skin cancer surgery: clinical/pathological criteria and their impact on oncological outcomes and therapeutic choices. A systematic review.
Bussu F, Daloiso A, Pagliuca G, et al.
Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale 2025; (45(Suppl. 1)):S121-S136 doi:10.14639/0392-100X-suppl.1-45-2025-N1121.
PMID: 40400382 - 8
Histologically Agressive Basal Cell Carcinoma With Particular Emphasis On Galeal Infiltration Of The Scalp.
Requena C, Serra-Guillén C, Sanmartín O
Actas dermo-sifiliograficas 2022; (113(6)):575-582 doi:10.1016/j.ad.2022.01.026.
PMID: 35339267 - 9
Basal Cell Carcinoma Perineural Invasion and Suggestive Signs of Perineural Invasion-Findings and Perspectives.
Niculet E, Bobeica C, Onisor C, et al.
Life (Basel, Switzerland) 2023; (13(6)) doi:10.3390/life13061406.
PMID: 37374188 - 10
Depth of Invasion of Aggressive and Nonaggressive Basal Cell Carcinoma.
Wetzel M, Strickley J, Haeberle MT, Brown TS
The Journal of clinical and aesthetic dermatology 2019; (12(3)):12-14.
PMID: 30988868 - 11
Non-melanoma skin cancer: United Kingdom National Multidisciplinary Guidelines.
Newlands C, Currie R, Memon A, et al.
The Journal of laryngology and otology 2016; (130(S2)):S125-S132 doi:10.1017/S0022215116000554.
PMID: 27841126
This page explains basal cell carcinoma biopsy and pathology terms for informational purposes only and does not constitute medical advice. Your pathologist, dermatologist, or surgeon can interpret your report and recommend care for your situation.